AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) stock declined by 3.22% at the last close, whereas the ACRX stock price gained by 3.52% in the after-hours trading session. AcelRx Pharmaceuticals is a specialty pharmaceutical business specializing in the research and marketing of novel therapeutics for medically supervised environments.
ACRX stock’ Current Development ‘
AcelRx Pharmaceuticals reported the publishing of actual data in patients having total hip or total knee replacement that showed a shorter hospital stay and lower opioid usage when sublingual sufentanil was used to address acute pain instead of usual IV opioids. The journal of orthopaedic experience and innovation ran the article.
Dr. Lawrence Wiesner and Dr. Christian Tvetenstrand of the United Health Services Orthopedic Center in Vestal, New York, and the Southern Tier Surgical Clinic in Johnson City, New York, co-authored the article “Reduced opioid use and hospital stay in patients undergoing total knee or total hip arthroplasty when treated with sublingual sufentanil compared to standard analgesic care.”
About the study,
In this study, 110 individuals were assessed, with 53 being given SST prospectively and 57 being in the historical comparison group. The groups demonstrated the same patient demographics, anaesthetic procedures, and surgical types. Patients in both groups were on average over 65 years old, and over half of them had a severe systemic illness, which the American Society of Anesthesiologists classified as Physical Status III.
What was the hindrance?
The control group was a historical batch, however, both groups got surgery in the time when the COVID epidemic was going on and anaesthetic procedures, analgesic regimens, and discharge criteria were all the same across the two groups, with the exception of SST dose. Another drawback is that just one SST dosage was tested, and it’s unknown whether greater opioid reductions might be achieved if a second or third dose was used during the patient’s postoperative stay.
